NATCO Pharma gets CDSCO approval for Generic Semaglutide Injection, launch set for March 2026
NiveshIQ
NSE: NATCOPHARM · Pharma
NATCO Pharma Ltd.
₹935.95▲ ₹10.90 (+1.18%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on NATCOPHARM. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About NATCO Pharma Ltd.
NATCO Pharma Limited is a leading Indian pharmaceutical company with a diverse portfolio of finished dosage formulations, APIs, and intermediates. The company generates revenue primarily from oncology, central nervous system, pain management, and cardiovascular care products. Its key revenue drivers include formulations in various therapeutic areas, such as cancers and APIs in oncology and central nervous system categories. Recent developments include the approval of Eribulin Mesylate Injection by the US FDA in collaboration with Lupin. The company has a strong competitive position in the Indian and international markets, with a focus on research and development, manufacturing, and marketing. Despite a decline in revenue and profit in FY26, growth is expected to resume from FY28, driven by
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹3,999 Cr +47.70% | ₹4,430 Cr +10.80% | ₹4,078 Cr -7.90% |
| EBITDA Margin | 43.86% | 49.57% | 42.52% |
| Net Profit | ₹1,388 Cr +94.10% | ₹1,883 Cr +35.70% | ₹1,418 Cr -24.70% |
| EPS | ₹77.51 | ₹105.26 | ₹79.20 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
Stocks to Watch Today: Reliance Industries, ICICI Bank, HDFC Bank, NATCO Pharma, Oberoi Realty, RBL Bank, Poonawalla Fincorp, Turtlemint in focus on 20 July
Alembic and Partner NATCO Pharma Secure Tentative USFDA Nod for Generic Lynparza
🔒
+ 3 more stories about NATCO Pharma Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q4FY26 results: revenue ₹739 Cr, PAT ₹269 Cr, EPS ₹14.96, EBITDA margin 27.8%. Growth context: revenue YoY -40.6%, revenue QoQ +14.2%, PAT QoQ +78.1%. Street verdict: beat, revenue surprise +1.0%, PAT surprise +9.9%.
Management's near-term growth strategy hinges on product launches, approvals, and therapy-mix improvement, with new prod...
Natco Pharma's FY26 financial performance was marked by revenue of ₹4, 078 Cr, PAT of ₹1, 418 Cr, and an EBITDA margin o...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for NATCOPHARM
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track NATCOPHARM alongside your other holdings
Unlock full NATCOPHARM research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for NATCO Pharma Ltd.?
NiveshIQ detects active intelligence signals for NATCO Pharma Ltd. (NATCOPHARM) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for NATCO Pharma Ltd.?
NATCO Pharma Ltd. operates in the Pharma sector with a market capitalisation of ₹2,104,361.9L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.